Puma Biotechnology (PBYI)

• Market cap: $249M
• 1 day: -0.6%
• 5 days: -1.59%
• 1 month: -6.07%
• 3 months: -0.8%
• 6 months: 43.9%
• Year to date: 58.65%
• 1 year: 63.91%
• 5 years: -55.2%
• 10 years: -93.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Employees: 172